Atrial Fibrillation in Patients With Cardiomyopathy: Prevalence and Clinical Outcomes From Real-World Data

被引:23
|
作者
Buckley, Benjamin J. R. [1 ,2 ,3 ]
Harrison, Stephanie L. [1 ,2 ,3 ]
Gupta, Dhiraj [2 ]
Fazio-Eynullayeva, Elnara [4 ]
Underhill, Paula [4 ]
Lip, Gregory Y. H. [1 ,2 ,3 ,5 ]
机构
[1] Univ Liverpool, Liverpool Ctr Cardiovasc Sci, William Henry Duncan Bldg, Liverpool L7 8TX, Merseyside, England
[2] Liverpool Heart & Chest Hosp, Liverpool, Merseyside, England
[3] Univ Liverpool, Dept Cardiovasc & Metab Med, Inst Life Course & Med Sci, Liverpool, Merseyside, England
[4] TriNetX LLC, London, England
[5] Aalborg Univ, Dept Clin Med, Aalborg, Denmark
来源
关键词
atrial fibrillation; cardiomyopathy; comorbidity; MACE; preventive cardiology; secondary prevention; CATHETER ABLATION; HYPERTROPHIC CARDIOMYOPATHY; SYSTOLIC DYSFUNCTION; HEART-FAILURE; MORBIDITY; RISK;
D O I
10.1161/JAHA.121.021970
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background Cardiomyopathy is a common cause of atrial fibrillation (AF) and may also present as a complication of AF. However, there is a scarcity of evidence of clinical outcomes for people with cardiomyopathy and concomittant AF. The aim of the present study was therefore to characterize the prevalence of AF in major subtypes of cardiomyopathy and investigate the impact on important clinical outcomes. Methods and Results A retrospective cohort study was conducted using electronic medical records from a global federated health research network, with data primarily from the United States. The TriNetX network was searched on January 17, 2021, including records from 2002 to 2020, which included at least 1 year of follow-up data. Patients were included based on a diagnosis of hypertrophic, dilated, or restrictive cardiomyopathy and concomitant AF. Patients with cardiomyopathy and AF were propensity-score matched for age, sex, race, and comorbidities with patients who had a cardiomyopathy only. The outcomes were 1-year mortality, hospitalization, incident heart failure, and incident stroke. Of 634 885 patients with cardiomyopathy, there were 14 675 (2.3%) patients with hypertrophic, 90 117 (7.0%) with restrictive, and 37 685 (5.9%) with dilated cardiomyopathy with concomitant AF. AF was associated with significantly higher odds of all-cause mortality (odds ratio [95% CI]) for patients with hypertrophic (1.26 [1.13-1.40]) and dilated (1.36 [1.27-1.46]), but not restrictive (0.98 [0.94-1.02]), cardiomyopathy. Odds of hospitalization, incident heart failure, and incident stroke were significantly higher in all cardiomyopathy subtypes with concomitant AF. Among patients with AF, catheter ablation was associated with significantly lower odds of all-cause mortality at 12 months across all cardiomyopathy subtypes. Conclusions Findings of the present study suggest AF may be highly prevalent in patients with cardiomyopathy and associated with worsened prognosis. Subsequent research is needed to determine the usefulness of screening and multisdisciplinary treatment of AF in this population.
引用
收藏
页数:14
相关论文
共 50 条
  • [41] Suboptimal Management of Patients with Non-valvular Atrial Fibrillation: Real-world Clinical Setting
    Lau, Wallis C. Y.
    Chan, Esther W.
    Wong, Ian C. K.
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2015, 24 : 380 - 380
  • [42] Do clinical trial cohorts reflect the complexities of real-world patients with chronic atrial fibrillation?
    Ball, J.
    Carrington, M. J.
    Stewart, S.
    EUROPEAN HEART JOURNAL, 2012, 33 : 955 - 955
  • [43] Rivaroxaban Precision Dosing Strategy for Real-World Atrial Fibrillation Patients
    Konicki, Robyn
    Weiner, Daniel
    Herbert Patterson, J.
    Gonzalez, Daniel
    Kashuba, Angela
    Cao, Yanguang Carter
    Gehi, Anil K.
    Watkins, Paul
    Powell, J. Robert
    CTS-CLINICAL AND TRANSLATIONAL SCIENCE, 2020, 13 (04): : 777 - 784
  • [44] Real-World Rivaroxaban and Apixaban Levels in Asian Patients With Atrial Fibrillation
    Lin, Shin-Yi
    Kuo, Ching-Hua
    Yeh, Shin-Joe
    Tsai, Li-Kai
    Liu, Yen-Bin
    Huang, Chih-Fen
    Tang, Sung-Chun
    Jeng, Jiann-Shing
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2020, 107 (01) : 278 - 286
  • [45] Ischaemic stroke and bleeding rates in 'real-world' atrial fibrillation patients
    Ogilvie, Isla M.
    Welner, Sharon A.
    Cowell, Warren
    Lip, Gregory Y. H.
    THROMBOSIS AND HAEMOSTASIS, 2011, 106 (01) : 34 - 44
  • [46] Real-world performance of the atrial fibrillation monitor in patients with a subcutaneous ICD
    Baalman, Sarah W. E.
    Mittal, Suneet
    Boersma, Lucas V. A.
    Perschbacher, Dave
    Brisben, Amy J.
    Mahajan, Deepa
    Groot, Joris R.
    Knops, Reinoud E.
    PACE-PACING AND CLINICAL ELECTROPHYSIOLOGY, 2020, 43 (12): : 1467 - 1475
  • [47] Stroke Prevention in Atrial Fibrillation What Is Real World, and What Do Real-World Data Reveal?
    Healey, Jeff S.
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2018, 72 (02) : 154 - 155
  • [48] Real-world variability in dabigatran levels in patients with atrial fibrillation: comment
    Douxfils, J.
    Chatelain, B.
    Dogne, J. -M.
    Mullier, F.
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2015, 13 (06) : 1166 - 1168
  • [49] Real-world variability in dabigatran levels in patients with atrial fibrillation: reply
    Chan, N. C.
    Hirsh, J.
    Ginsberg, J. S.
    Eikelboom, J. W.
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2015, 13 (06) : 1168 - 1169
  • [50] Clinical impact of inappropriate DOAC dosing in atrial fibrillation: Insights from a real-world registry
    Yildirim, Mustafa
    Hund, Hauke
    Mueller-Hennessen, Matthias
    Katus, Hugo A.
    Frey, Norbert
    Giannitsis, Evangelos
    Salbach, Christian
    IJC HEART & VASCULATURE, 2025, 56